Key points are not available for this paper at this time.
To provide an overview on the current use of belimumab (BLM) in SLE patients in clinical practice and to examine its efficacy in terms of standardized outcomes, drug survival, as well as patient and safety profiles.
Altabás‐González et al. (2024) studied this question.